Delivery System

Abstract

The present application relates to the development of a delivery system incorporating a Moringa oleifera extract containing Moringa oleifera coagulation protein, thus providing a consumer product containing the natural extract that provides an antimicrobial effect. One aspect of the invention relates to a delivery system comprising a carrier and a hydrophobic formulation, the carrier comprising Moringa oleifera coagulation protein (MOCP). Embodiments of the invention include where the carrier is a polymeric shell and where the hydrophobic formulation comprises an active ingredient. A further aspect of the invention provides a consumer product comprising the delivery system of the invention.

Description

[Technical field]

[0001] The present invention relates to a delivery system. More specifically, the present invention relates to the use of an extract from Moringa oleifera containing MOCP as an antimicrobial agent. The delivery system of the present invention can be incorporated into consumer products, including hygiene products and food products.

[0002] There is an increasing consumer demand for products containing natural extracts that provide antibacterial benefits. Such natural products not only improve the quality of the products they are incorporated into, but also inspire consumer trust as they are known from nature and therefore are not perceived as artificial additives.

[0003] Moringa oleifera is a tree of the Moringaceae family, native to the Indian subcontinent. The tree has been cultivated since ancient times for its beneficial food and health properties. In particular, the Moringa tree offers many multifunctional benefits, including highly nutritious leaves (iron, calcium, vitamin C, and other micronutrients), seeds that can be pressed to obtain cosmetic oils and biofuels, and even water-soluble cationic proteins that have been used as antibacterial flocculants to purify water for centuries. Moringa trees are nutritious trees that provide shade and are crucial to communities in need of increased access to clean water and nutrients.

[0004] The Moringa oleifera plant contains various coagulation peptides (Moringa oleifera coagulation proteins (MOCPs)) that bind to anionic surfaces and render certain bacteria and microorganisms inviable. Coagulation proteins can be cationic, and such proteins can be antimicrobial because they interact electrostatically with anionic biological surfaces, membranes, and microorganisms. Cationic materials are also likely to promote attachment and interaction with biological surfaces and fibers, such as skin, hair, and natural fabrics, which are generally recognized to be negatively charged, and could potentially be used to enhance the adhesion performance, persistence, and strength of various active agents.

[0005] In the present invention, the inventors have attempted to develop a delivery system incorporating Moringa oleifera extract containing MOCP. In this way, the present invention provides a consumer product containing a natural extract that provides antimicrobial benefits.

[0006] Summary of the Invention In the invention claimed herein, MOCP, or an extract from Moringa oleifera containing MOCP, is used as a water-soluble emulsifier, and therefore functions as a carrier to enable delivery of hydrophobic formulations, including flavor or fragrance actives.

[0007] Accordingly, a first aspect of the present invention provides a delivery system comprising a carrier and a hydrophobic formulation, wherein the carrier comprises Moringa oleifera coagulation protein (MOCP).

[0008] Since MOCP is an antibacterial agent, the delivery system has natural antibacterial activity.

[0009] For the avoidance of doubt, the carrier has an outer coating of Moringa oleifera clotting protein (MOCP).

[0010] In an embodiment of this aspect of the invention, the MOCP is in an extract from Moringa oleifera.

[0011] In a further embodiment of the delivery system of the present invention, the carrier is a polymeric shell. Preferably, the MOCP is external to the polymeric shell, or alternatively, the MOCP is incorporated within the polymeric shell.

[0012] In further embodiments of the delivery system of the present invention, the polymeric shell comprises a material selected from aminoplast-based, polyurea-based, or polyurethane-based.

[0013] In a further embodiment of the delivery system of the present invention, the carrier is a polymeric carrier matrix comprising a material selected from modified starches, maltodextrins, gums, non-animal proteins, polysaccharides, and / or soluble fibers.

[0014] In a further embodiment of the delivery system of the present invention, the delivery system is a polymeric carrier matrix that comprises a polymeric shell.

[0015] In further embodiments of the delivery system of the present invention, the delivery system further comprises one or more emulsifiers and / or antimicrobial agents.

[0016] In a further embodiment of the delivery system of the present invention, the delivery system is in the form of spray-dried particles.

[0017] In a further embodiment of the delivery system of the present invention, the extract from Moringa oleifera is present in an amount between 1% and 95% by weight of the delivery system.

[0018] In a further embodiment of the delivery system of the present invention, the hydrophobic formulation comprises an active ingredient. Preferably, the active ingredient is a fragrance, flavor, dye, dye precursor, catalyst from a chemical reaction, adhesive, reactive material for adhesive applications, pharmaceutical active, preservative, cosmetic active, emollient, conditioner, emollient skin / hair product, plant protection active (e.g. insecticide, fungicide, herbicide, bactericide), water repellent, flame retardant, sunscreen, solvent, or food ingredient.

[0019] A further aspect of the present invention provides a consumer product comprising the delivery system of the present invention. Preferably, the consumer product is a perfumed or flavored consumer product. Preferably, the consumer product is a food product comprising the delivery system of the present invention in the form of a dry beverage.

[0020] A further aspect of the invention provides a delivery system of the invention for use as an antibacterial agent.

[0021] Further aspects of the invention include methods of reducing microbial growth comprising the delivery system of the invention. In some embodiments, the methods may include incorporating the delivery system of the invention into a consumer hygiene product (e.g., a surface cleaning product) or incorporating the delivery system of the invention into a food product. [Brief description of the drawings]

[0022] [Figure 1] FIG. 1 shows extruded particles, left: Example N, right: Example O. Scale bar represents 5 mm.

[0023] Detailed Description of the Invention Unless otherwise specified, percentages (%) are intended to represent weight percent of the composition.

[0024] The term "antimicrobial agent" is intended to have its usual meaning in the art, i.e., an agent that kills or reduces the growth of microorganisms. As used herein, "microorganisms" include bacteria, archaea, fungi, protozoa, algae, and viruses.

[0025] When referring to "particles" or "powder composition", percentages (%) are given relative to the dry composition.

[0026] By "delivery system" is understood in this specification in particular the protection and / or control of the release of perfume formulations and perfume active ingredients contained within the perfume formulation.

[0027] By "microcapsules" or the like in the present invention is meant capsules having a particle size distribution in the micron range (e.g. a mean diameter (d(v,0.5)) comprised between about 1 and 3000 μm, preferably between 1 and 500 μm, more preferably between 1 and 50 μm) and comprising an outer polymeric shell and an inner continuous oil phase surrounded by the outer shell. Coacervates are also part of the present invention.

[0028] The present invention relates to a delivery system incorporating a carrier comprising Moringa oleifera coagulation protein, and various embodiments and uses of the carrier system.

[0029] Moringa oleifera coagulation proteins have antimicrobial activity, are natural, vegan, plant-derived, and associated with health and wellness. This provides a versatile means of providing antimicrobial benefits to a wide range of flavor and fragrance applications, including confectionery, oral care, beverages, home care, surface care, body / hair care (rinse-off, deodorant / AP, dry shampoo), fabric / laundry care, and air care. Additionally, because MOCP is a natural emulsifier, it can be incorporated into many different delivery technologies, including spray-dried powders and microcapsules that bring antimicrobial benefits to many consumer applications.

[0030] Few natural water-soluble emulsifiers with antibacterial activity are known and may be combined with other natural antibacterial oils, e.g. oils (eucalyptus, peppermint, lemongrass, orange, rosemary, thyme, etc.).

[0031] In the invention claimed herein, MOCPs or extracts from Moringa oleifera containing MOCPs are used as emulsifiers, thus acting as carriers enabling the delivery of hydrophobic formulations, including flavor or fragrance actives.

[0032] Moringa oleifera coagulation protein As mentioned above, the Moringa oleifera plant contains one or more cationic double-helical peptides (the main functional peptide is called Moringa oleifera coagulation protein (MOCP)) that bind to anionic surfaces and render certain bacteria and microorganisms inviable. Therefore, MOCPs can be used as natural antimicrobial agents.

[0033] MOCPs are well known and have been genetically characterized for many years, e.g., Samineni et al (2019) Environ. Sci. Technology 53, 12706-12714 and Freire et al (2015) PLOS ONE PLOS ONE | DOI:10.1371 / journal.pone.0119871 provide information on a large number of MOCP peptides.

[0034] Examples of MOCPs that can be used in the present invention include Mo2.1 (SEQ ID NO:1), MoCBP (SEQ ID NO:2), MoCBP3.1 (SEQ ID NO:3), MoCBP3.2 (SEQ ID NO:4), MoCBP3.3 (SEQ ID NO:5), and MoCBP3.4 (SEQ ID NO:6). However, all MOCPs derived from Moringa are encompassed by this aspect of the invention.

[0035] Thus, the Moringa oleifera coagulation protein used in the delivery system of the present invention can be prepared using molecular biology methods.

[0036] The nucleic acid sequence encoding MOCP protein can be inserted into an expression vector and / or can be included in a chimeric gene inserted into an expression vector to produce MOCP in a host cell or a non-human host organism. The vector for inserting a transgene into the genome of a host cell is well known in the art, and includes plasmids, viruses, cosmids, and artificial chromosomes. The binary vector or cointegration vector into which the chimeric gene is inserted can also be used to transform a host cell.

[0037] A non-human host organism suitable for carrying out the bioproduction of MOCPs may be any non-human multicellular or unicellular organism. In one embodiment, the non-human host organism used to carry out the embodiments herein in vivo is a plant, a prokaryote, or a fungus. Any plant, prokaryote, or fungus may be used. In another embodiment, the non-human host organism used to carry out the methods of the embodiments herein in vivo is a microorganism. Any microorganism may be used, for example, the microorganism may be a bacterium or a yeast, such as E. coli or Saccharomyces cerevisiae.

[0038] To prepare MOCP protein, a host organism or host cell is cultured under conditions that promote the production of MOCP protein.When the host is a unicellular organism, the conditions that promote the production of MOCP protein can include adding appropriate cofactors to the host culture medium.Furthermore, the culture medium can be selected to maximize the synthesis of MOCP protein.

[0039] Once produced, the MOCP protein can be isolated from the host cell using standard protein purification methods, for example, the MOCP protein can be prepared using standard chromatographic methods.

[0040] Alternatively, the MOCP is in an extract from Moringa oleifera.

[0041] MOCPs are present in extracts from, for example, seed coatings, leaf tissue, etc. Moringa seed protein and leaf protein powders are available from a number of sources (e.g., Lifetime Tea, Chandler, AZ, USA).

[0042] Examples of how Moringa oleifera extracts containing MOCPs can be prepared for use in the present invention are provided in the accompanying Examples and hereinafter.

[0043] Moringa seed protein powder is added to distilled water in an amount of about 1 g protein to 2.33 g distilled water. The solution is mixed with a homogenizer for 5 minutes and then heated at about 60°C for 30 minutes. After mixing with a homogenizer again for 5 minutes, the solution is cooled to room temperature and the pH is adjusted to 6 with NaOH solution. The Moringa seed protein preparation is then centrifuged and the supernatant is collected. This is the Moringa oleifera extract used in the present invention.

[0044] Moringa leaf protein is added to distilled water in an amount of about 1 g protein to 5.66 g distilled water. The solution is mixed with a homogenizer for 5 minutes and then heated at about 60°C for 30 minutes. After mixing with a homogenizer again for 5 minutes, the solution is cooled to room temperature and the pH is adjusted to 6 with NaOH solution. The Moringa leaf protein preparation is then centrifuged and the supernatant is collected. This is also the Moringa oleifera extract used in the present invention.

[0045] As shown in the accompanying examples, the present inventors have determined the amount of MOCP in an extract from Moringa oleifera required to obtain an antibacterial effect.

[0046] An additional aspect of the present invention is treating a substrate with a sufficient amount of the composition to provide an antimicrobial effect.

[0047] The term "effective" means inhibiting the growth of or killing a microorganism.

[0048] Preferably, the extract from Moringa oleifera is present in an amount of 1% to 95% by weight of the total weight of the delivery system, more preferably in an amount of 10% to 85% by weight.

[0049] Hydrophobic Formulations The present invention relates to a delivery system incorporating a hydrophobic compound.

[0050] By "hydrophobic formulation" is meant any hydrophobic formulation (single component or mixture of components) that forms a two-phase dispersion when mixed with water.

[0051] In a preferred embodiment of the invention, the hydrophobic formulation is defined by a logP of greater than 1, more preferably greater than 2.

[0052] Preferably, the hydrophobic formulation comprises one or more hydrophobic active ingredients. Preferably, the active ingredient is a fragrance, flavor, dye, dye precursor, catalyst from a chemical reaction, adhesive, reactive material for adhesive applications, pharmaceutical active, preservative, cosmetic active, emollient, conditioner, emollient skin / hair product, plant protection active (e.g. insecticide, fungicide, herbicide, bactericide), water repellent, flame retardant, sunscreen, solvent, or food ingredient.

[0053] In a preferred embodiment of the invention, the active ingredient is selected from flavors and fragrances. For the purposes of the present invention, the term "flavor or fragrance" includes flavor or fragrance ingredients or compositions of both natural and synthetic origin currently used in the flavor and / or fragrance industry. This includes single compounds and mixtures. Specific examples of such flavor or fragrance ingredients can be found in the current literature, for example Fenaroli's Handbook of flavour ingredients, 1975, CRC Press; Synthetic Food adjuncts, 1947 by MB Jacobs, edited by Van Nostrand; or Perfume and Flavor Chemicals by S. Arctander, 1969, Montclair, New Jersey (USA). Many other examples of current flavor and / or fragrance ingredients can be found in the available patent and general literature. The flavor or fragrance ingredients can be present in the form of a mixture with solvents, auxiliaries, additives and / or other ingredients, generally those currently used in the flavor and fragrance industry.

[0054] "Flavoring ingredients" are well known to those skilled in the art of flavoring as being capable of imparting flavor or taste to a consumer product or modifying the taste and / or flavor of said consumer product, as well as its texture or mouthfeel.

[0055] A "perfuming ingredient" is understood herein to be a compound used as an active ingredient in a perfume preparation or composition to impart a hedonic effect when applied to a surface. In other words, such a compound must not only have an odor, but must be recognized by those skilled in the perfumery industry as being capable of imparting or modifying the odor of a composition or article or surface in a positive or pleasant way in order to be considered a perfuming ingredient. Furthermore, this definition is intended to include compounds that do not necessarily have an odor, but are capable of modulating the odor of a perfume composition, perfumed article, or perfumed surface, thereby modifying the odor of such composition, article, or surface by the user. This also includes ingredients and compositions that neutralize malodors. The term "malodor neutralizing ingredient" is used herein to mean a compound that can reduce the perception of malodors, i.e., the perception of an odor that is unpleasant or unpleasant to the human nose, by counteracting and / or masking the malodor. In certain embodiments, these compounds have the ability to react with the main compounds responsible for known malodors. This reaction reduces the airborne level of the malodorous substance, thereby reducing the perception of the malodor.

[0056] Thus, in one embodiment, the hydrophobic active ingredient comprises at least 5% by weight, preferably at least 10% by weight, preferably at least 20% by weight, more preferably at least 30% by weight, most preferably at least 40% by weight of a compound having a vapor pressure of at least 0.007 Pa at 25°C, preferably at least 0.1 Pa at 25°C, more preferably at least 1 Pa at 25°C, most preferably at least 10 Pa at 25°C, all percentages being defined by weight relative to the total weight of the hydrophobic active ingredient. Compounds that meet these criteria are generally considered to have a volatile character and therefore have an odor or flavor. Thus, the method of the present invention allows for the efficient encapsulation of large amounts of volatile ingredients.

[0057] According to certain embodiments, the hydrophobic active agent is a mixture of a perfume oil and a neutral carrier oil selected from cosmetically acceptable solvents or emollients such as silicone oils, mineral oils, alkanes, paraffins, triglycerides, fatty acids, or gums, or mixtures thereof. Examples of such products include, but are not limited to, Neobee, Ester gum, Damar gum, isopropyl myristate, or paraffins such as Gemseal.

[0058] According to certain embodiments, the hydrophobic active agent is a mixture of flavor oil and a neutral carrier oil selected from triglycerides, fatty acids, or gums, or mixtures thereof. Examples of such products include, but are not limited to, Neobee, Ester gum, or Damar gum.

[0059] For the purposes of the present invention, the vapor pressure is determined by calculation. Thus, to determine the value of the vapor pressure of a particular compound or component of a hydrophobic active ingredient, the method disclosed in the "EPI suite"; 2000 US Environmental Protection Agency is used.

[0060] The amount of hydrophobic active ingredient in the delivery system of the present invention is preferably comprised between 1% and 90% by weight, more preferably between 10% and 60% by weight, based on the total weight of the delivery system.

[0061] Also, when spray dried, it can be present not only within or on the microcapsules, but also within the matrix.

[0062] Carrier A delivery system is understood herein to protect and / or control the release of hydrophobic formulations, especially hydrophobic formulations that contain active ingredients.

[0063] By carrier or carrier material, it is understood herein that the material of the carrier is suitable for trapping, encapsulating or holding a certain amount of the hydrophobic compound. To be considered a carrier material, the carrier material must trap, encapsulate or hold a certain amount of the hydrophobic compound.

[0064] Typically, when the delivery system is in matrix form, the carrier material is a matrix material and the delivery system should preferably entrap at least 5% by weight, preferably at least 10% by weight, and even more preferably at least 15% by weight of the hydrophobic compound based on the total weight of the delivery system.

[0065] In one embodiment of the present invention, the carrier is a core-shell microcapsule.

[0066] In such an embodiment, the MOCP is on the outside of the core-shell microcapsule.

[0067] In another embodiment, the MOCP is incorporated within a core-shell microcapsule. "Internal" in this invention includes cases where the MOCP is incorporated such that it is encapsulated within the capsule, as well as cases where the MOCP is incorporated into the material that forms the shell itself.

[0068] Typically, when the delivery system is in the form of a core-shell microcapsule, the carrier is the shell, which constitutes 1% to 50% by weight of the delivery system.

[0069] When the delivery system is in the form of a spray-dried powder, the hydrophobic compound comprises 10% to 30% of the weight of the delivery system.

[0070] When the microcapsules are in the form of a slurry with water, the amount of hydrophobic compound will be less than 50% of the total weight of the delivery system.

[0071] In certain embodiments, the carrier or carrier material is a solid carrier material, i.e., an emulsion or a solvent is not a carrier or carrier material.

[0072] In certain embodiments, the delivery system is a core-shell microcapsule, or the delivery system is in matrix form (i.e., the hydrophobic formulation entrapped within a polymer matrix, such as a monomeric, oligomeric, or polymeric carrier matrix). For clarity, it is understood that when the delivery system is a core-shell microcapsule, the hydrophobic formulation is contained within the core, which is surrounded or entrapped by the shell. When the delivery system is in matrix form, the hydrophobic formulation is entrapped within the matrix of the carrier, such as a monomeric, oligomeric, or polymeric carrier matrix, by adsorption within the matrix.

[0073] When the carrier is a monomeric, oligomeric, or polymeric carrier matrix, it is understood herein that the hydrophobic compound is entrapped in the monomeric, oligomeric, or polymeric carrier matrix by dispersion within the monomeric, oligomeric, or polymeric carrier matrix.

[0074] In certain embodiments, the carrier material comprises a monomeric, oligomeric, or polymeric carrier material, or a mixture of two or more thereof. An oligomeric carrier is a carrier in which 2 to 10 monomeric units are covalently linked. For example, when the oligomeric carrier is a carbohydrate, the oligomeric carrier can be sucrose, lactose, raffinose, maltose, trehalose, maltodextrin, and fructooligosaccharide.

[0075] Examples of monomeric carrier materials are, for example, glucose, fructose, mannose, galactose, arabinose, fucose, sorbitol, mannitol.

[0076] The polymeric carrier has more than 10 monomer units covalently linked together.

[0077] Non-limiting examples of the latter include polyvinyl acetate, polyvinyl alcohol, dextrin, maltodextrin, natural or modified starches, vegetable gums, pectin, xanthan, alginates, carrageen, as well as cellulose derivatives such as carboxymethylcellulose, methylcellulose or hydroxyethylcellulose, and generally any material currently used for encapsulating volatile substances. Preferably, the polymeric carrier comprises maltodextrin. According to a particular embodiment, it comprises maltodextrin and modified starch, such as alkenyl-succinylated starch.

[0078] The carrier material is preferably present in an amount of 25-95% by weight, preferably 30-60% by weight, more preferably 40-55% by weight (based on the total weight of the delivery system).

[0079] In a preferred embodiment, the polymeric carrier material may further comprise a fireproofing agent, preferably selected from the group consisting of sodium silicate, potassium silicate, sodium carbonate, sodium bicarbonate, monoammonium phosphate or carbonate, diammonium phosphate, mono-, di- or trisodium phosphate, sodium hypophosphite, melamine cyanurate, chlorinated hydrocarbons, talc, and mixtures thereof.

[0080] Where the delivery system is a core-shell microcapsule having a shell, it is understood herein that the hydrophobic compound is contained in the core surrounded by the shell of the microcapsule.

[0081] The nature of the polymeric shell of the microcapsules of the present invention may vary. By way of non-limiting example, the shell may be aminoplast-based, polyurea-based or polyurethane-based. The shell may also be hybrid, i.e. organic-inorganic, such as a hybrid shell composed of at least two types of inorganic particles crosslinked together, or even a shell resulting from the hydrolysis and condensation reaction of a polyalkoxysilane macromonomer composition.

[0082] According to one embodiment, the shell comprises an aminoplast copolymer such as melamine-formaldehyde or urea-formaldehyde, or crosslinked melamine formaldehyde or melamine glioxal.

[0083] According to another embodiment, the shell is polyurea-based, for example, but not limited to, made from an isocyanate-based monomer and an amine-containing crosslinker, such as guanidine carbonate and / or guanazole. A preferred polyurea microcapsule comprises a polyurea wall that is a reaction product of polymerization between at least one polyisocyanate containing at least two isocyanate functional groups and at least one reactant selected from the group consisting of amines (e.g., water-soluble guanidine salts and guanidine); a colloidal stabilizer or emulsifier; and an encapsulated perfume. However, the use of amines can be omitted.

[0084] According to a particular embodiment, the colloidal stabilizer comprises an aqueous solution of 0.1% to 0.4% polyvinyl alcohol and 0.6% to 1% cationic copolymer of vinylpyrrolidone and quaternized vinylimidazole (all percentages are defined by weight relative to the total weight of the colloidal stabilizer). According to another embodiment, the emulsifier is an anionic or amphiphilic biopolymer, preferably selected from the group consisting of gum arabic, soy protein, gelatin, sodium caseinate, and mixtures thereof.

[0085] According to another embodiment, the shell is polyurethane-based, made from, for example, but not limited to, polyisocyanates and polyols, polyamides, polyesters, and the like.

[0086] The preparation of aqueous dispersions / slurries of core-shell microcapsules is well known to those skilled in the art. In one aspect, the microcapsule wall material can include any suitable resin, including melamine, glyoxal, polyurea, polyurethane, polyamide, polyester, and the like. Suitable resins include reaction products of aldehydes and amines, and suitable aldehydes include formaldehyde and glyoxal. Suitable amines include melamine, urea, benzoguanamine, glycoluril, and mixtures thereof. Suitable melamines include methylol melamine, methylated methylol melamine, imino melamine, and mixtures thereof. Suitable ureas include dimethylol urea, methylated dimethylol urea, urea-resorcinol, and mixtures thereof. Materials suitable for manufacture can be obtained from one or more of Solutia Inc. (St Louis, Missouri USA), Cytec Industries (West Paterson, New Jersey USA), and Sigma-Aldrich (St. Louis, Missouri USA).

[0087] According to certain embodiments, the core-shell microcapsules are formaldehyde-free capsules. A typical method for preparing an aminoplast formaldehyde-free microcapsule slurry includes: 1) a) Melamine, or melamine and two NH 2 At least one C containing functional group 1 ~C 4 Polyamine components in the form of mixtures with compounds; b) Glyoxal and C 4~6 An aldehyde component in the form of a mixture of 2,2-dialkoxy-ethanal and, optionally, glyoxalate, said mixture having a glyoxal / C ratio of 1 / 1 to 10 / 1. 4~6 an aldehyde component having a molar ratio of 2,2-dialkoxy-ethanal; and c) a protonic acid catalyst; preparing an oligomeric composition comprising or obtained by reacting together the reaction products of 2) preparing an oil-in-water dispersion, the droplet size being 1 to 600 μm, I. Oil; II. Water medium; III. The oligomeric composition obtained in at least step 1; IV. AC 4 ~C 12 and their biuret, triuret, trimer, trimethylolpropane adducts, and mixtures thereof; and / or B. The following formula A-(Oxirane-2-ylmethyl) n [Wherein, n represents 2 or 3, and 1 represents a C group optionally containing 2 to 6 nitrogen atoms and / or oxygen atoms. 2 ~C 6 represents a group] Di- or tri-oxirane compounds of At least a crosslinker selected from the group consisting of i. optionally, two NH 2 C containing functional groups 1 ~C 4 compound; A process comprising: 3) heating the dispersion; 4) cooling the dispersion; Includes.

[0088] This method is described in more detail in WO 2013 / 068255, the contents of which are incorporated by reference.

[0089] According to another embodiment, the shell of the microcapsule is polyurea or polyurethane based. Examples of methods for preparing polyurea and polyurethane based microcapsule slurries are described, for example, in WO 2007 / 004166, EP 2300146, EP 2579976, the contents of which are also incorporated by reference. Typically, the method for preparing polyurea or polyurethane based microcapsule slurries includes: a) dissolving at least one polyisocyanate having at least two isocyanate groups in oil to form an oil phase; b) preparing an aqueous solution of an emulsifier or colloidal stabilizer to form an aqueous phase; c) adding an oil phase to an aqueous phase to form an oil-in-water dispersion, the average droplet size being comprised between 1 and 500 μm, preferably between 5 and 50 μm; d) applying conditions sufficient to induce interfacial polymerization to form microcapsules in the form of a slurry. Includes.

[0090] Preferred Embodiments of the Delivery System In a preferred embodiment of the invention, the delivery system is in the form of a matrix carrier and has the following composition: [Table 1]

[0091] Thus, in a preferred embodiment of the present invention, the delivery system is a matrix carrier and comprises 10%-95% Moringa seed extract (preferably 20%-85%), 5%-50% hydrophobic compound (preferably 15%-30%), 0%-5% additional emulsifier (preferably 0.5%-2%), and 0%-85% of other ingredients listed herein (preferably 0%-50%).

[0092] In a further preferred embodiment of the invention, the delivery system is in the form of a core-shell microcapsule and has the following composition: [Table 2]

[0093] Thus, a preferred embodiment of the present invention is in a core-shell microcapsule format and comprises 1%-30% Moringa seed extract (preferably 10%-20%), 10%-60% hydrophobic compound (preferably 20%-50%), 0.1%-9% polyisocyanate monomer (preferably 0.2%-7.5%), 0%-5% water (preferably 0%-2%), and 0%-5% additional emulsifier (preferably 0%-2%).

[0094] Further components of the delivery system of the present invention In one embodiment of the invention, the delivery system further comprises one or more emulsifiers and / or antimicrobial agents.

[0095] "Emulsifying agents" include modified starches, gums, proteins, saponins, and similar such agents known in the art.

[0096] "Antimicrobial agents" include alkaloids, phenolics, essential oils, saponin, chitosan, nisin, lauryl alginate, and similar such agents known in the art.

[0097] consumer products A further aspect of the invention provides a consumer product comprising the delivery system of the invention.

[0098] Preferably, the consumer product is a perfumed or flavored consumer product.

[0099] Non-limiting examples of suitable perfumed consumer products include perfumes such as fine perfumes, splashes or eau de parfums, colognes or shaving or aftershave lotions; fabric care products such as liquid or solid detergents, fabric softeners, fabric deodorants, ironing water, paper or bleach, carpet cleaners, curtain care products; body care products such as hair care products (e.g. shampoos, stains or hairsprays, color care products, hair styling products, dental care products), disinfectants, intimate care products; cosmetics (e.g. skin creams or lotions, vanishing creams or deodorants or antiperspirants (e.g. sprays or roll-ons), depilatories, tanning products or sunscreens or after-sun products, nail products, skin cleansing, make-up); or skin care products (e.g., perfumed soaps, shower or bath mousses, oils, or gels, or hygiene products or foot / hand care products and hand sanitizers); air care products such as deodorants or "ready to use" powder deodorants that can be used in domestic spaces (rooms, refrigerators, cupboards, shoes, or cars) and / or public spaces (hall, hotel, mall, etc.); or home care products such as mold removers, furniture care, wipes, surface coatings for masks, dish detergents, or hard surface (e.g., floor, bathroom, toilet, or window) cleaners; leather care products; car care products such as polishes, waxes, or plastic cleaners. Alternatively, in some embodiments, the consumer product is a body care product or a home care product.

[0100] Additionally, the delivery systems of the present invention can be added to flavored consumer products.

[0101] For the sake of clarity, "flavored consumer product" is intended to refer to an edible product that may be a food or beverage, fried or not, frozen or not, low fat or not, marinated, battered, refrigerated, dehydrated, instant, canned, reconstituted, retorted, or preserved. Thus, the flavored article according to the present invention comprises the extract of the present invention and optional beneficial agents that correspond to the taste and flavor profile of the desired edible product, e.g., flavor cube.

[0102] The nature and type of ingredients of the food or beverage do not warrant a more detailed description here and the person skilled in the art can select them on the basis of general knowledge and depending on the nature of the product.

[0103] Typical examples of such flavored consumer products include: Flavours or seasonings, such as stocks, flavour cubes, powder mixes, flavoured oils, sauces (e.g. relishes, barbecue sauces, dressings, gravies, sweet and / or sour sauces), salad dressings, or mayonnaise; · meat-based products such as chicken, beef or pork based products, seafood, minced meat or fish sausages; · Soups such as clear soups, cream soups, chicken or beef soups, or tomato or asparagus soups; Carbohydrate-based products such as instant noodles, rice, pasta, potato flakes or fried foods, noodles, pizza, tortillas, wraps; Dairy or fatty products such as spreads, cheese, regular or low fat margarine, butter / margarine blends, butter, peanut butter, shortening, processed cheese, or flavored cheese; · Snacks, biscuits (e.g. chips or crisps) or savory products such as egg products, potato / tortilla chips, microwave popcorn, nuts, pretzels, mochi, rice crackers; · Imitation foods, such as dairy products (e.g. modified cheeses made from fats and thickeners), or seafood or meat (e.g. vegetarian meat substitutes, veggie burgers) or similar products; pet or animal food; or Hot drinks (e.g. tea and coffee), carbonated soft drinks, alcoholic drinks (e.g. whiskey), ready-to-drink drinks or powdered soft drinks Examples include:

[0104] In a preferred embodiment, the delivery system of the present invention is added to chewing gum or other similar products.

[0105] In a further preferred embodiment, the delivery system of the present invention is formulated in a dry flavored consumer product, such as a dry beverage.

[0106] The proportions at which the delivery system of the present invention can be incorporated into the various aforementioned products vary within wide ranges of values, depending on the nature and desired organoleptic effect of the consumer product to which the flavor is to be added, as well as the nature of the co-ingredients in a given base when the composition according to the present invention is mixed with perfuming ingredients, flavoring ingredients, solvents, or additives commonly used in the art.

[0107] For example, for flavored consumer products, typical concentrations are on the order of 10 ppm to 100,000 ppm, more preferably 1,000 ppm to 50,000 ppm, and even more preferably 3,000 ppm to 10,000 ppm of the delivery systems of the present invention, based on the weight of the consumer product in which they are incorporated.

[0108] Hereinafter, the present invention will be further described in detail by the following examples which illustrate the advantages and benefits of the present invention.

[0109] Working Example Hereinafter, the present invention will be further described in detail by the following examples which illustrate the advantages and benefits of the present invention.

[0110] Methods: Protein content and protein solubility Moringa seed protein and leaf protein powders were obtained from Lifetime Tea (Chandler, AZ, USA). Compositional analysis was performed on both Moringa seed and leaf proteins, including percent carbon, hydrogen, and nitrogen. Total protein content was calculated using a multiplication factor of 6.25 for nitrogen content. Protein solubility of Moringa seed protein was measured by preparing 200 grams of aqueous solution containing 20% ​​protein powder by weight with deionized water. Solution samples were prepared in triplicate and thoroughly mixed at 60°C for 5 minutes to ensure complete hydration. The hydration solution was adjusted to pH 6.0 with 3.0% sodium hydroxide. The protein solution was then centrifuged at 6000 RPM for 5 minutes to separate the soluble and insoluble fractions. All supernatant was removed and the exact weight was recorded. Compositional analysis of these supernatants was performed to determine the nitrogen content. The protein content obtained from the solution samples was used along with the protein content determined for the powder samples (i.e., 52% for Moringa seed protein powder) to calculate the amount of soluble protein and protein solubility. The results are shown in the table below. Moringa seed protein powder has a much higher protein content than Moringa leaf protein (52% vs. 24% by weight). The protein solubility of a 20% Moringa seed protein solution is 66% by weight. [Table 3]

[0111] Example 1: Preparation of soluble moringa seed protein Moringa seed protein was obtained from Lifetime Tea (Chandler, AZ, USA). Protein content was determined by multiplying the nitrogen measurement by 6.25 and is 52% by weight (assuming the nitrogen content of the protein is 16%). Soluble Moringa seed protein was prepared according to the following protocol.

[0112] 1. Add 60 grams of Moringa seed protein to 140 grams of deionized water in a 500 mL container. 2. Using a Silverson L4RT homogenizer, mix the solution at 7000 rpm for 5 minutes. 3. Keep the protein solution in the water batch at 60° C. for 30 minutes 4. Mix again with the solution at 7000 rpm for 5 minutes. 5. Cool to room temperature and adjust pH to 6 with 3% NaOH solution. 6. Centrifuge the samples at 6000 rpm for 5 minutes. 7. Collect the supernatant 8. A portion of the collected supernatant is freeze-dried to obtain soluble moringa protein (A-1). 9. A portion of the collected supernatant was spray-dried to obtain soluble moringa protein (A-2). A mini Buchi dryer B-290 was used with an inlet air temperature of about 180°C and an outlet air temperature of about 85°C.

[0113] Example 2: Preparation of soluble Moringa leaf protein Moringa leaf protein was obtained from Lifetime Tea (Chandler, AZ, USA). Protein content was determined by multiplying the nitrogen measurement by 6.25 and is 24% by weight (assuming the nitrogen content of the protein is 16%). Soluble Moringa leaf protein was prepared according to the following protocol.

[0114] 1. Add 30 grams of Moringa seed protein to 170 grams of deionized water in a 500 mL container. 2. Using a Silverson L4RT homogenizer, mix the solution at 7000 rpm for 5 minutes. 3. Keep the protein solution in the water batch at 60° C. for 30 minutes 4. Mix the solution again at 7000 rpm for 5 minutes. 5. Cool to room temperature and adjust pH to 6 with 3% NaOH solution. 6. Centrifuge the samples at 6000 rpm for 5 minutes. 7. Collect the supernatant and freeze-dry it to obtain soluble Moringa leaf protein (B).

[0115] Example 3: Preparation of spray-dried medium chain triglyceride (MCT) powder MCT emulsions were prepared by mixing and homogenizing (Silverson L4TR, 7000 rpm for 5 min) MCT with various wall material solutions. The compositions of the emulsions are listed in the table below. Spray-dried MCT powders were prepared by spray drying the prepared MCT emulsions using a Mini Buchi dryer B-290 at an inlet air temperature of about 180°C and an outlet air temperature of about 85°C. [Table 4]

[0116] Example 4: Preparation of Moringa Microcapsules (Protocol 1 Preparation of Moringa-functionalized microcapsules) Microcapsules were prepared according to the following process and then post-functionalized by adding 20 wt % soluble Moringa seed powder (as described above).

[0117] 1) Dissolve gum arabic in deionized water. 2) Takenate D-110N (a trimethylolpropane adduct of xylylene diisocyanate, supplied by Mitsui Chemicals, Inc., Japan, a 75% solution of polyisocyanate in ethyl acetate) is dissolved in Dorisyl containing 5% by weight of Uvinul A Plus (a UV tracer used for adhesion). 3) Add the oil phase to the water phase and homogenize for 2 minutes at 10,000 rpm (Ultra-Turrax T25, 18G probe) 4) Heat the emulsion at 70°C for 4 hours and then cool to room temperature.

[0118] (Protocol 2 Preparation of Moringa Microcapsules) The microcapsules were prepared according to the following process.

[0119] 1) Dissolve soluble moringa seed powder (Lifetime Tea, process described above) in deionized water. 2) Takenate D-110N is dissolved in Dorisyl containing 5% by weight Uvinul A Plus (a UV tracer used for adhesion). 3) Add the oil phase to the water phase and homogenize for 2 minutes at 10,000 rpm (Ultra-Turrax T25, 18G probe) 4) Heat the emulsion at 70°C for 4 hours and then cool to room temperature. The microcapsule formulation can be seen in the table below: [Table 5]

[0120] Example 5: Attachment of Microcapsules (Microcapsule attachment protocol) A 500 mg Caucasian small brown hair swatch was wetted with 40 mL tap water (39°C) directed to the mount using a 140 mL syringe. Excess water was gently squeezed out once, and 0.1 mL of a model surfactant mixture (8.6 g SLES (sodium lauryl ether sulfate), 5.0 g CAPB (cocamidopropyl betaine), 6.3 g 4 wt% Salcare® SC60, and 30.1 g deionized water, pH 5.5) containing microcapsules loaded with a UV tracer (Uvinul A Plus) was applied with a 100 μL positive displacement pipette. The surfactant mixture was spread 10 times horizontally and 10 times vertically using the thumb and index finger of a gloved hand. 50 mL was then applied to each side of the swatch directed to the mount, and the swatch was rinsed with 100 mL tap water (39°C). Water was allowed to run down the length of the swatch, rinsing the 10 cm swatch thoroughly. Excess water was gently squeezed out and then the hair swatch was cut and placed into a pre-weighed 20 mL scintillation vial. This process was repeated three times, after which the vial containing the cut hair was dried in a vacuum oven at 50-60 °C (100 Torr) for at least 5 hours. After the drying process, the vial was weighed again to determine the mass of hair in the vial. Controls were also prepared by placing 0.1 mL of the model surfactant mixture containing microcapsules into an empty vial. Then, 4 mL of 200 proof ethanol was added to each vial and they were sonicated for 60 minutes. After sonication, the samples were filtered through a 0.45 μm PTFE filter and analyzed by HPLC using a UV detector. To determine the percent attachment of microcapsules from the model surfactant mixture, the amount of Uvinul extracted from the hair sample was compared to the amount of Uvinul extracted from the control sample. Deposition results were normalized to 400 mg of hair and are reported as the average of triplicate measurements.

[0121] As shown in Table 6, the adhesion of both Moringa microcapsules (I and J) was better than the control (G). [Table 6]

[0122] Example 6: Preparation of spray-dried moringa microcapsules Spray dried Moringa microcapsules were prepared using soluble Moringa seed protein in a Mini Buchi dryer B-290 with an inlet air temperature of about 180° C. and an outlet air temperature of about 85° C. The spray dried formulation is listed in the table below. [Table 7]

[0123] Example 7: Antibacterial evaluation (Preparation of bacterial suspension) Bacterial suspensions of Escherichia coli ATCC25922 and Staphylococcus aureus ATCC6538 were prepared as follows: Stock cultures stored at -80°C were subcultured on agar plates and incubated at 37°C for 24 hours to obtain single colonies; A single colony from the primary culture was inoculated onto agar plates to obtain secondary cultures; A single colony from the secondary culture was inoculated into Mueller-Hinton (MH) broth medium and incubated overnight at 37°C and 180 rpm; An aliquot of the overnight culture was inoculated into 50 ml of fresh broth medium and incubated at 37°C and 180 rpm. OD 600nm When the target value for each strain was reached (see Table 8), the cells were harvested by centrifugation at 5000 rpm for 10 min and then resuspended in the same volume of fresh broth medium as before centrifugation. An aliquot (1.1 ml) of each cell suspension was diluted with 200 ml of 2x MH broth medium to provide the bacterial solution for MIC testing. [Table 8]

[0124] (Preparation of sample solution) Sample solutions of test materials were prepared in MilliQ water for MIC testing of E. coli and S. aureus strains. Briefly, a 10% stock solution was prepared in MilliQ water, and then 1:2 serial dilutions were prepared in MilliQ water to obtain a total of six solutions of test materials. Aliquots (100 μl) of each solution were used for MIC testing. The final concentrations tested for each material were 5%, 2.5%, 1.25%, 0.625%, 0.3125%, 0.15625%, and 0.0781%.

[0125] (MIC and MBC Test Procedures) The MIC test was performed in a 96-well plate. Aliquots (100 μl) of the sample solution were diluted in 10 5 ~10 6 The bacteria were mixed with 100 μl of a bacterial solution in growth medium at a concentration of cfu / ml. Each solution was repeated three times.

[0126] The 96-well plates were incubated at 37°C and 180 rpm for 24 h. After incubation, 10 μL of 0.2% resazurin was added to each well. The plates were further incubated at 37°C for 4 h. Wells that turned pink were considered to indicate microbial growth. The minimum inhibitory concentration (MIC) was determined as the lowest concentration at which no growth was observed. The mean MIC value of triplicates was calculated for each strain.

[0127] Viable cells in each well were counted by the spiral plate method. Briefly, 10 of the cell suspension was counted in each well by transferring an aliquot (50 μL) from each well into 4950 μL of 0.85% saline. -2 Dilutions were prepared. Aliquots (50 μL) were plated onto TSA plates using an Eddy Jet2 spiral plater in E-50 mode. The minimum bactericidal concentration (MBC) was determined as the lowest concentration that gave no bacterial colonies on TSA.

[0128] (MIC and MBC test results) Concentrations tested: 5%, 2.5%, 1.25%, 0.625%, 0.3125%, 0.15625%, and 0.0781%. [Table 9]

[0129] The spray-dried powder containing maltodextrin and MCT (Example E) did not show significant activity against either E. coli or S. aureus, as both the MIC and MBC were greater than 5%, suggesting that MCT and maltodextrin are ineffective against E. coli or S. aureus.

[0130] The effective concentration of soluble moringa seed protein against S. aureus ATCC6538 was determined to be 0.3%-0.6% (Examples A1 and A2), while soluble moringa leaf protein (Example B) appears to be ineffective against E. coli and S. aureus. Example C contains approximately 80% moringa seed protein and their effective concentration against S. aureus was determined to be 0.3-1.25%. These results clearly demonstrate that the incorporation of soluble moringa seed protein into a spray-dried delivery system can provide antimicrobial benefits.

[0131] The antibacterial activity of Quillaja saponin has been reported in the literature. Example D, which contains both Moringa seed protein and Quillaja saponin, showed a lower MIC against E. coli and a higher MIC against S. aureus compared to Example C. This suggests that the activity against E. coli can be enhanced by formulating a water-soluble antibacterial agent with Moringa seed protein.

[0132] The antibacterial activity of eugenol has been reported in the literature. Example F, which contains eugenol in the oil phase, showed a lower MIC against E. coli and a higher MIC against S. aureus compared to Example C. This suggests that the combination of Moringa seed protein with a hydrophobic antibacterial agent can enhance the activity against E. coli.

[0133] Microcapsules made with soluble Moringa seed protein showed positive activity against S. aureus. Example J showed a high MIC of 5% against S. aureus due to the low concentration of Moringa seed protein (i.e., 16% by weight of the microcapsule slurry). The microcapsule slurry was spray-dried with soluble Moringa seed protein to obtain powdered microcapsules containing about 80% soluble Moringa seed protein. Example K showed an MIC of 0.3125% and an MBC of 2.5% against S. aureus.

[0134] This clearly indicates that Moringa seed proteins can be entrapped in microcapsules to impart antibacterial properties.

[0135] Example 8: Further Data Supporting the Invention (Preparation of Moringa Seed Protein Extract) Soluble moringa seed protein powder was prepared using the protocol in Example 1 without adjusting the pH of the protein solution during the extraction process.

[0136] Preparation of spray-dried powder MCT emulsions were prepared by mixing and homogenizing (Silverson L4TR, 7000 rpm for 5 minutes) MCT with various wall material solutions. The compositions of the emulsions are listed in Table 10 below. Spray-dried powders were prepared by spray drying the prepared MCT emulsions using a Mini Buchi dryer B-290 at an inlet air temperature of about 180° C. and an outlet air temperature of about 85° C. The spray-dried powders were used for antibacterial testing. [Table 10]

[0137] MIC and MBC test results of Moringa samples Determination of MIC and MBC of bacterial strains using broth dilution assay Bacterial suspensions of Escherichia coli, Staphylococcus aureus, Staphylococcus hominis, and Corynebacterium striatum were prepared as follows: Stock cultures stored at -80°C were subcultured on agar plates and incubated at 37°C for 24 hours to obtain single colonies; A single colony from the primary culture was inoculated onto agar plates to obtain secondary cultures; A single colony from the secondary culture was inoculated into broth medium and incubated overnight at 37°C and 180 rpm; An aliquot of the overnight culture was inoculated into 50 ml of fresh broth medium and incubated at 37°C and 180 rpm. OD 600nm When the target value for each strain was reached (see Table 11), the cells were harvested by centrifugation at 5000 rpm for 10 minutes and then resuspended in fresh 2x broth medium of the same volume as before centrifugation. An aliquot (1.1 ml) of each cell suspension was diluted with 200 ml of 2x broth medium to prepare the bacterial solution for MIC and MBC tests.

[0138] As previously described, duplicate samples at concentrations of 5%, 2.5%, 1.25%, 0.625%, 0.3125%, 0.15625%, and 0.0781% were tested to determine the MIC and MBC for bacterial strains. The samples are shown in Table 11. [Table 11]

[0139] MIC and MBC results [Table 12] [Table 13]

[0140] E. coli and S. aureus were selected for potential hygiene applications, and S. hominis and C. striatum were selected for deodorant (DEO) applications. The results show that Examples L and M have activity against S. aureus, S. hominis, and C. striatum with MICs ranging from 0.31% to 0.63% and MBCs ranging from 0.63% to 2.5%. All these results suggest that spray-dried powders produced using Moringa seed protein extract as an emulsifier and carrier can provide antibacterial properties for multiple purposes including hygiene applications, oral care, food and beverage applications, APDO for reducing personal malodor, and many other applications.

[0141] Example 9: Extrusion Prototype A ZSE18 co-rotating twin screw extruder (L / D18, Leistritz, Branchburg, NJ, USA) was used to encapsulate medium chain triglycerides (MCTs) using moringa seed protein as the carrier material. The extruder is equipped with eight barrels, each with an independently controlled temperature.

[0142] All materials were premixed homogeneously in a Stephan mixer. The mixture was then fed into the extruder by a loss-in-weight feeder at a flow rate of 2.5 kg / hr. The glass transition temperature (T g A small amount of water was injected into the extruder to keep the melt temperature above 20 °C. The temperature setpoints of the extruder barrel from the feed to the die end ranged from 20 to 100 °C. The screw speed was kept constant at 200 rpm. The melt was extruded through a die plate with holes of 2.5 mm diameter. After steady-state extrusion conditions, the strands exiting the die were collected and ground to different particle sizes. The samples were stored at room temperature (approximately 23 °C) and no caking was observed even after 2 weeks of storage, as shown in Figure 1. [Table 14]

[0143] (Protein sequences used in the present invention) [ka]

Claims

1. A delivery system comprising a carrier and a hydrophobic formulation, wherein the carrier comprises Moringa oleifera coagulated protein (MOCP).

2. The delivery system according to claim 1, wherein the MOCP is in an extract from Moringa oleifera, or the MOCP is in an extract from Moringa oleifera and the MOCP is incorporated within core-shell microcapsules.

3. The delivery system according to claim 1 or 2, wherein the carrier is a core-shell microcapsule, or the carrier is a core-shell microcapsule and the MOCP is outside the core-shell microcapsule.

4. The delivery system according to claim 3, wherein the core-shell microcapsule comprises a material selected from aminoplast-based, polyurea-based, or polyurethane-based materials.

5. The delivery system according to claim 1 or 2, wherein the carrier is a polymeric carrier matrix comprising a material selected from modified starch, maltodextrin, gum, protein, polysaccharide, and / or soluble fiber.

6. The delivery system according to claim 1 or 2, which is a polymeric carrier matrix comprising a polymeric shell.

7. The delivery system according to claim 1 or 2, further comprising one or more emulsifiers and / or antibacterial agents.

8. The delivery system according to claim 1 or 2, which is in the form of spray-dried particles.

9. The delivery system according to claim 1 or 2, wherein the extract from Moringa oleifera is present in an amount of 1% to 95% of the total weight of the delivery system.

10. The delivery system according to claim 1 or 2, wherein the hydrophobic complex contains one or more active ingredients.

11. The delivery system according to claim 10, wherein the active ingredient is a fragrance, a flavor, a dye, a dye precursor, a catalyst from a chemical reaction, an adhesive, a reactive substance for adhesive use, a pharmaceutically active substance, a preservative, a cosmetic active substance, a skin softener, a conditioner, a soothing skin / hair product, a plant protection active substance (e.g., an insecticide, a fungicide, a herbicide, a bactericide), a water repellent, a flame retardant, a sunscreen, a solvent, or a food ingredient.

12. A consumer product comprising the delivery system according to claim 1 or 2.

13. The consumer product according to claim 12, which is a perfumed consumer product or a flavored consumer product.

14. The delivery system according to claim 1 or 2 for use as an antibacterial agent.

15. A method for reducing the growth of microorganisms, comprising incorporating the delivery system of claim 1 or 2 into a consumer hygiene product or incorporating the delivery system of claim 1 or 2 into a food.